ISRCTN12290106进行中（未招募）4 期
An open-label randomised trial to assess the efficacy of post-operative ferric maltol vs standard care for anaemia following colorectal cancer surgery
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant is willing and able to give informed consent for participation in the study.
- •2. Male or Female, aged 18+ years.
- •3. Diagnosed with histologically or radiologically diagnosed colorectal adenocarcinoma.
- •4. Anaemic at point of diagnosis of colorectal adenocarcinoma (Defined as haemoglobin 10 g/L below WHO criteria: 120 g/L for males and 110 g/L for females, to account for a 10% fluctuation in Hb)
- •5. Undergoing surgery for colorectal cancer with curative intent.
- •6. Date of planned surgery is =14 days from date of planned initiation of recruitment.
- •7. Able (in the investigators opinion) and willing to comply with all study requirements.
- •8. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.
排除标准
- •1. Patients with mental health issues or learning disabilities resulting in their inability to consent to the study
- •2. Patients who do not have a histological diagnosis of colorectal adenocarcinoma
- •3. Female participants who are pregnant, lactating or planning a pregnancy during the course of the study.
- •4. Patients with evidence of iron overload or disturbances in utilisation of iron as stated in the product SPC.
- •5. Previous gastric, small bowel or colorectal surgery (where =50% of stomach or terminal ileum has been resected)
- •6. Chemotherapeutic treatment within the last 4 weeks.
- •7. Known previous anaemia not attributable to colorectal carcinoma (i.e. anaemia in patients with well established, inflammatory disorders)
- •8. Known haematological disease.
- •9. Features necessitating urgent surgery (e.g. obstructive symptoms).
- •10. Previous allergy to intravenous or oral iron or related iron products.
- •11. Patients who are unable to consent.
- •12. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.
- •13. Participants who have participated in another research study involving an investigational product in the past 12 weeks
- •14. Confirmed liver or lung metastases
研究者
相似试验
招募中
4 期
A randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART): MARCH studyHIVInflammatory and Immune System - Other inflammatory or immune system disordersInfection - Acquired immune deficiency syndrome (AIDS / HIV)ACTRN12611000816954niversity of New South Wales, Kirby Institute560
进行中（未招募）
1 期
An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancerCTIS2023-508219-21-00Jazz Pharmaceuticals Ireland Limited243
尚未招募
3 期
An open-label randomized trial of zanidatamab for advanced HER2-positive biliary tract cancerCTRI/2024/08/072371Jazz Pharmaceuticals Ireland Limited
已完成
不适用
Randomized open-label trial to evaluate the efficacy of artesunate-amodiaquin for seasonal malaria chemoprevention in suburban school of Bamako, SirakMalariaPACTR201409000782309Malaria Research and Training Center/Faculty of Medecine and Dentistry/University of Sceinces, Techniques and Technologies200
尚未招募
Unknown
To evaluate the efficacy of medicated enema therapy and external oleation therapy followed by oral medication in the management of hip joint pain.CTRI/2024/07/070233ational Institute of Ayurveda